OCGN
Ocugen, Inc. NASDAQ$1.85
Pre-mkt
$1.55
-16.22%
Mkt Cap $626.3M
52w Low $0.64
58.0% of range
52w High $2.73
50d MA $1.88
200d MA $1.48
P/E (TTM)
-7.8x
EV/EBITDA
-6.9x
P/B
—
Debt/Equity
-2.7x
ROE
557.7%
P/FCF
-7.1x
RSI (14)
—
ATR (14)
—
Beta
2.81
50d MA
$1.88
200d MA
$1.48
Avg Volume
7.9M
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene thera…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | BMO | -0.06 | -0.06 | +0.0% | 1.96 | -1.0% | -11.2% | -17.9% | -15.3% | -9.7% | +17.3% | — |
| Nov 5, 2025 | BMO | -0.06 | -0.07 | -21.7% | 1.41 | -0.7% | -2.1% | -3.5% | -4.3% | -5.7% | -5.0% | — |
| Aug 1, 2025 | BMO | -0.06 | -0.05 | +16.7% | 0.99 | +0.6% | +0.6% | -3.9% | -3.6% | +0.6% | +0.5% | — |
| May 9, 2025 | BMO | -0.06 | -0.05 | +16.7% | 0.67 | +1.9% | +4.5% | +4.9% | +3.7% | +5.9% | +13.2% | — |
| Mar 5, 2025 | BMO | -0.05 | -0.05 | +0.0% | 0.57 | +1.2% | +10.0% | +6.4% | -3.0% | -4.7% | +0.6% | — |
| Nov 14, 2024 | BMO | -0.05 | -0.05 | +0.0% | 1.00 | +2.0% | -6.1% | -8.9% | -12.6% | -8.2% | -9.9% | — |
| Aug 8, 2024 | BMO | -0.06 | -0.04 | +33.3% | 1.28 | -0.8% | -2.3% | +1.6% | +3.1% | +0.0% | +2.3% | — |
| Apr 16, 2024 | BMO | -0.06 | -0.04 | +33.3% | 1.59 | +0.6% | -9.4% | -17.0% | -17.0% | -22.0% | -21.4% | — |
| Mar 26, 2024 | BMO | -0.06 | -0.03 | +50.0% | 1.73 | +0.0% | +2.9% | -5.2% | -11.0% | -20.2% | -12.7% | — |
| Nov 9, 2023 | BMO | -0.08 | -0.06 | +25.0% | 0.37 | +0.0% | -2.3% | -0.9% | +1.5% | +3.0% | -1.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $1.92 | $1.98 | +3.1% | +1.6% | +2.1% | -2.6% | -8.9% | -5.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.92 | $1.98 | +3.1% | +1.6% | +2.1% | -2.6% | -8.9% | -5.7% |
| Mar 5 | Chardan Capital | Maintains | Buy → Buy | — | $1.96 | $1.94 | -1.0% | -11.2% | -17.9% | -15.3% | -9.7% | +17.3% |
| Jan 20 | Chardan Capital | Maintains | Buy → Buy | — | $1.69 | $1.71 | +1.2% | -1.2% | -11.8% | -2.4% | -1.8% | -5.9% |
| Sep 19 | Chardan Capital | Maintains | Buy → Buy | — | $1.40 | $1.34 | -4.3% | -4.3% | -0.7% | +18.6% | +17.1% | +8.6% |
| Aug 4 | Chardan Capital | Maintains | Buy → Buy | — | $0.99 | $1.00 | +0.6% | +0.6% | -3.9% | -3.6% | +0.6% | +0.5% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.98 | $1.07 | +9.1% | +5.0% | +6.0% | +5.0% | +0.3% | -1.1% |
| Jun 24 | Chardan Capital | Maintains | Buy → Buy | — | $0.98 | $1.07 | +9.1% | +5.0% | +6.0% | +5.0% | +0.3% | -1.1% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.67 | $0.68 | +1.9% | +4.5% | +4.9% | +3.7% | +5.9% | +13.2% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.67 | $0.68 | +1.9% | +4.5% | +4.9% | +3.7% | +5.9% | +13.2% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Ocugen disclosed forward-looking statements, likely regarding clinical trials or commercialization plans, signaling potential near-term catalysts but increased execution risk that investors should monitor closely.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Ocugen disclosed forward-looking statements via press release and presentations, signaling upcoming announcements about clinical or commercial developments that investors should monitor for material catalysts affecting the biotech stock's trajectory.
Mar 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This boilerplate risk disclosure suggests Ocugen faces significant operational uncertainties that could negatively impact results; investors should review detailed SEC filings before trading.
Mar 20
8-K · 8.01
!! High
Ocugen, Inc. -- 8-K 8.01: Material Event / Announcement
Ocugen won expedited hearing approval for its shareholder vote petition, allowing the company to declare stockholder approval of its Share Increase Proposal from the 2024 Annual Meeting.
Mar 4
8-K
Ocugen, Inc. -- 8-K Filing
Ocugen released Q4 and full-year 2025 financial results on March 4, 2026, with a conference call scheduled for 8:30 a.m. to discuss business performance and updates.
Mar 4
8-K · 5.02
!!! Very High
Ocugen, Inc. -- 8-K 5.02: Executive Change
Ocugen appoints Ms. Johnson-Greene as principal financial officer while she resigns from the board, signaling potential leadership restructuring that investors should monitor for strategic implications.
Feb 9
Data updated apr 26, 2026 4:52pm
· Source: massive.com